Biomodulatory therapy induces durable remissions in multi-system Langerhans cell histiocytosis (2022) Harrer DC, Jakob M, Vogelhuber M, Lueke F, Utpatel K, Corbacioglu S, Herr W, et al. Journal article Immune modulatory effects of Idelalisib in stromal cells of chronic lymphocytic leukemia (2021) Handl SA, Von Heydebrand F, Völkl S, Oostendorp RAJ, Wilke J, Kremer A, Mackensen A, Lutzny-Geier G Journal article Low dose stereotactic irradiation and dexamethasone in primary cerebral light chain deposition disease (LCDD) (2021) Authier D, Hegenbart U, Pohl F, Rosenwald A, Kircher S, Menhart K, Perl M, et al. Journal article Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma (2021) Nordmo C, Glehr G, Altenbuchinger M, Spang R, Ziepert M, Horn H, Staiger AM, et al. Journal article Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations–a registry based analysis (2021) Middeke JM, Teipel R, Roellig C, Stasik S, Zebisch A, Sill H, Kramer M, et al. Journal article Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects (2020) Jansen L, Merz M, Engelhardt M, Weisel K, Scheid C, Straka C, Langer C, et al. Journal article Ibrutinib treatment leads to H3K27ac redistribution in chronic lymphocytic leukemia (2020) Lambe A, Barth N, Papakonstantinou N, Xanthopoulos C, Gounari M, Stamatopoulos K, Taher L, Kostareli E Conference contribution Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population (2020) Ludwig H, Poenisch W, Knop S, Egle A, Hinke A, Schreder M, Lechner D, et al. Journal article Response to daratumumab in rituximab-resistant EBV-associated PTLD following allogenic stem cell transplantation from an EBV seronegative donor (2019) Strunz PP, Schmalzing M, Heidemeier A, Rasche L, Einsele H, Kortuem KM Journal article Detection of hemophagocytic extremely multinucleated giant plasma cells after rituximab/low-dose lenalidomide treatment in CD20+ multiple myeloma (2019) Schelker RC, Grube M, Reichle A, Wagner B, Herr W, Evert M, Vogelhuber M Journal article